TRT+: Testosterone Propionate

Before the convenience of weekly cypionate or 90-day pellets, there was a molecule synthesised from the processing of over 1,000 pounds of bull testicle tissue. Testosterone propionate, first marketed as Testoviron by Schering in 1936, was the compound that proved esterification could control a hormone's release rate. It established the entire foundation of modern clinical endocrinology.

Most clinicians today dismiss propionate as a pharmacological relic: too short-acting, too many injections, too much pain at the injection site. But a growing number of specialists are looking backward to move forward. Propionate's 2-to-4.5-day half-life and 10-to-12-hour Tmax are not limitations. They are the basis for a precision-first approach to hormone therapy that longer esters cannot match.

What follows is a documentation of what the clinical literature says about this molecule: where its speed is an advantage, where its sharp peaks create risk, and where the evidence is thinner than its advocates claim.

One of the most persistent claims about propionate is that it is less suppressive to the HPG axis than longer esters. The reasoning is intuitive: because propionate clears rapidly, the pituitary gets periodic "breaths" of GnRH signalling between doses, rather than the relentless suppression created by long-acting depots.

The Murine Evidence

• LH levels: Propionate-treated mice maintained LH at 0.348 IU/L, compared to 0.017 IU/L for long-acting pellets, and close to wild-type controls

• Time to pregnancy: Propionate group: 26 days. Long-acting group: 33 days

• Dosing schedule: Monday-Wednesday-Friday in the murine model (half-life of ~19 hours in mice)

The Human Reality Check

This is where the claim runs into a wall. The sources explicitly flag HPTA preservation as an overclaimed benefit. Human HPTA sensitivity is significantly higher than murine sensitivity. In human clinical data, sperm counts typically decline within weeks of starting any exogenous testosterone, reaching azoospermia within 3-4 months regardless of ester.

The murine data is biologically plausible and worth investigating. But treating it as validated human evidence is a step the literature does not support. No controlled human study has measured pulsatile LH/FSH secretion on propionate versus long-acting esters.